This is seen with the in vitro-transcribed (IVT) mRNA used in TAMs; after serial administration of IRF5/IKKβ-encoding nanoparticles, two potent pro-inflammatory agents, the nanocarrier can substantially reduce tumor progression and also reduce the density of M2-like macrophages in a mouse tumor model, along with increased numbers of inflammatory myeloid cells with distinct M1-type transcriptional profiles [143]. The gene discussed is IRF5; the disease is neoplasm.